A B S T R AC T
Background. Resistin is a major adipose tissue cytokine implicated in insulin resistance, inflammation and vascular damage. This cytokine is raised in patients with end-stage kidney disease (ESKD) but the relationship between resistin and major clinical outcomes has not been investigated in this population. Methods. We studied the mutual relationship between resistin and the two major adipokines (adiponectin and leptin) and the interaction between resistin and adiponectin (ADPN) and all-cause and cardiovascular (CV) mortality in a cohort of 231 haemodialysis patients followed up for 57 ± 44 months.
Results. Plasma resistin was substantially raised in ESKD patients when compared with healthy subjects (P < 0.001). On univariate analysis, resistin was related inversely to ADPN (r = −0.14, P = 0.04) and directly to C-reactive protein (r = 0.15, P = 0.03), but was largely independent of leptin (r = 0.08, P = 0.24) and the HOMA-IR index (r = −0.04, P = 0.51). During the follow-up, 165 patients died (96 for CV causes). On both univariate (all-cause mortality: P = 0.004; CV mortality P < 0.001) and multivariate (all-cause mortality: P = 0.01; CV mortality P < 0.001) Cox regression analyses, the effect of resistin on study outcomes was closely dependent on ADPN levels. There was a consistent excess risk for all-cause (P = 0.002) and CV mortality (P = 0.003) by plasma resistin (20 ng/mL) in patients in the first ADPN tertile, but no risk excess for these outcomes was apparent in patients in the third tertile.
Conclusion. This study indicates that resistin predicts death and fatal CV events depending on plasma ADPN levels. These findings underscore the importance of the interaction among adipokines for the prediction of adverse clinical outcomes in ESKD.
I N T R O D U C T I O N
Over the past decade, numerous clinical studies focusing on the relationship between two main adipokines, adiponectin (ADPN) and leptin, and major clinical events in end-stage kidney disease (ESKD) patients have been published [1] [2] [3] [4] [5] . Resistin is a cysteine rich molecule of the 'found in inflammatory zones' (FIZZ) proteins, which is synthesized in the adipose tissue [6, 7] and in macrophages [8, 9] . High levels of this peptide go along with inflammation and insulin resistance both in experimental models [6, 10, 11] and in vivo in man [12] [13] [14] . Interest in resistin in ESKD has been much limited and until now no study has tested the relationship between this cytokine and major clinical outcomes, including all-cause and cardiovascular (CV) death, in this population. The issue is of relevance because high resistin is associated with mortality and incident heart failure in patients with coronary heart disease (CHD) [15] or with acute myocardial infarction [16] . Furthermore, a most risky arrhythmia such as atrial fibrillation was predicted by resistin levels in the Framingham Heart study population [17] . Adipose tissue cytokines have mutual interrelationships and interact with abdominal obesity in determining death and CV events [4] . Furthermore, ADPN is a modifier of the relationship between leptin and fat mass in young individuals [18] and modulates the risk for type-2 diabetes by leptin in the general population [19] .
With this background in mind, we identified the functional correlates of circulating resistin in ESKD patients and studied the relationship between resistin, death and incident CV events as well as the interaction between resistin and the adipokine which emerged as its strongest functional correlate, ADPN, and all-cause and CV mortality.
S U B J E C T S A N D M E T H O D S

Protocol
The protocol was in conformity to the ethical guidelines of our institutions and informed consent was obtained from each participant. All blood samples for laboratory tests were taken during a mid-week non-dialysis day, between 8 a.m. and 1 p.m.
Patients and controls
We studied an incident-prevalent cohort of 231 haemodialysis patients (127 M and 104 F) who had been on regular dialysis treatment (RDT) for at least 6 months. The enrolment criteria in this cohort were no history of congestive heart failure (CHF) (defined as dyspnoea in addition to two of the following conditions-raised jugular pressure, bibasilar crackles, pulmonary venous hypertension or interstitial oedema on chest X-ray, requiring hospitalization or extra ultra-ultrafiltration), left ventricular ejection fraction >35% and no inter-current or terminal illnesses. Patients were treated thrice weekly with standard bicarbonate dialysis (Na 138 mMol/L, HCO 3 
Laboratory measurements
Blood sampling was performed after an overnight fast between 8.00 a.m. and 10.00 a.m., always during a mid-week non-dialysis. After 20-30 min of quiet resting in a semi-recumbent position, samples were taken into chilled EDTA vacutainers, placed immediately on ice, centrifuged within 30 min at −4°C and the plasma stored at −80°C before assay. Serum lipids, albumin, glucose, phosphate, and haemoglobin measurements were made using standard methods in the routine clinical laboratory. Plasma concentration of C-reactive protein (CRP), leptin and ADPN was measured according to methods described elsewhere [1] . Plasma levels of IL-6 and TNF-α were measured by using commercially available kits (R&D Systems, Minneapolis, MN, USA). The intra-assay coefficient of variation for these molecules ranged from 2.6 to 4.7% and inter-assay coefficient of variation from 4.5 to 5.8%. Plasma resistin was measured by ELISA (Bio Vendor Laboratory Medicine, Inc., Brno Czech Republic). The intra-assay coefficient of variation was 4.3% and the inter-assay coefficient of variation was 6.8%. The average plasma resistin in 41 healthy volunteers was 10.8 ± 6.2 ng/mL with a normal range spanning from 1.2 to 29.9 ng/mL. Serum insulin levels were measured by using a commercially available RIA kit (Sorin Saluggia, Vercelli, Italy). Insulin sensitivity was estimated by using the homoeostatic model assessment (HOMA-IR) index [i.e. plasma glucose level × ( plasma insulin level)/22.5].
Follow-up study After the initial assessment, patients were monitored for 57 ± 44 months (range: 0.2-155 months). During the follow-up period, fatal CV events (ECG documented myocardial infarctions, heart failure, ECG documented arrhythmia, strokes, peripheral vascular disease or major arterial or venous thrombotic episodes) and death from other causes were accurately recorded. Each death was reviewed and assigned an underlying cause by a panel of five physicians. As part of the review process, all available medical information regarding each death was collected. This information always included study and hospitalization records. In the case of an out-of-hospital death, family members were interviewed by telephone, for better assessment of the circumstances surrounding the death.
Statistical analysis
Data were expressed as means ± SD, median and interquartile range or as percent frequency, as appropriate. Comparisons among groups were made by P for linear trend. The association between two continuous variables was assessed by the Pearson product-moment correlation coefficients and between binary and continuous variables by the point-biserial correlation coefficient. Variables having a positively skewed distribution were log transformed (lg 10 ) before the correlation study.
The effect modification of ADPN (i.e. the interaction analysis) [20] on the relationship between resistin and all-cause and CV mortality was investigated by univariate and multivariate Cox regression analyses. In multivariate models, we included resistin, ADPN and their interaction term [resistin (20 ng/mL increase) * ADPN (tertiles)] as well as traditional risk factors (age, gender, smoking, systolic pressure, cholesterol, diabetes, previous CV events, BMI), factors peculiar to ESRD (haemoglobin, albumin, phosphate, dialysis vintage) and CRP. By this strategy, we built up models of adequate statistical power for all-cause mortality (at least 1 variable every 11 deaths). In these analyses, ADPN was modelled in terms of tertiles because this functional form was the one that optimized data fitting [21] . To account for over-fitting for CV mortality, a shrinkage analysis was performed [22] . The proportionality assumption was tested by analysing the Schoenfeld residuals and no violation was found. The hazard ratios of a fixed increase in resistin (20 ng/mL) across ADPN tertiles were calculated by the linear combination method. Data were expressed as hazard ratios, 95% CIs and P-values. All calculations were done by standard statistical packages (SPSS for Windows Version 9.0.1, 11 Mar-1999, Chicago, IL, USA; STATA/SE 9.0 StataCorp LP, TX, USA).
R E S U LT S
Patients
The study population included 231 haemodialysis patients (age: 60 ± 15 years; males: 55%) on RDT for a median time of 41 months (inter-quartile 21-106 months) (see Table 1 ). One hundred and fifteen patients (50%) had previous CV events, 35 were diabetic (15%) and 86 (37%) were habitual smokers (22 ± 16 cigarettes/day). Eighty-four patients (36%) were on anti-hypertensive treatment (59 on mono-therapy with ACE inhibitors, AT-1 antagonists, calcium channel blockers, alphaand beta-blockers and 25 on double or triple therapy with various combinations of these drugs). One hundred and twenty-six patients (55%) were treated with erythropoietin. Average urea Kt/V was 1.22 ± 0.27.
Correlates of plasma resistin
Plasma resistin in ESKD patients had a normal distribution with an average value of 117.2 ± 23.3 ng/mL which was ∼11 times higher than the average normal value (10.8 ± 6.2 ng/mL) and exceeded the upper limit (29.9 ng/mL) of the normal range in all patients (Figure 1 ). Plasma resistin was weakly 
Survival analysis
During the follow-up period, 165 patients died, 96 of them for CV causes. Resistin failed to significantly predict all-cause and CV mortality (P = NS). On univariate Cox regression analysis, patients in the lowest ADPN tertile had higher allcause mortality rate (19 deaths/100 persons year) when compared with those in the second (11 deaths/100 persons year) and third ADPN tertile (17 deaths/100 persons year) (P for trend = 0.02). The same analysis carried out for CV mortality provided similar results (ADPN, I tertile: 13 CV deaths/100 person years; II tertile: 6 CV deaths/100 persons year; III tertile: 8 CV deaths/100 persons year) (P for trend = 0.02). Formal interaction analysis showed that ADPN is a strong modifier of the relationship between resistin and study outcomes both on univariate (all-cause mortality: P for effect modification = 0.004; CV mortality: P for effect modification <0.001) or on multivariate Cox regression analyses (Table 2 and Figure 3) . Indeed, the risk excess for all cause and CV mortality portended by a fixed increase in resistin (20 ng/mL) was apparent and highly significant (all-cause mortality: P for effect modification = 0.01; CV mortality: P for effect modification <0.001) in patients with low ADPN (first ADPN tertile all-cause death, HR: 1.32, 95% CI: 1.11-1.58; CV death, HR: 1.42, 95% CI: 1.12-1.79), slight and not significant in those in the second tertile (all-cause death, HR: 1.10, 95% CI: 0.95-1.27; CV death, HR: 1.04, 95% CI: 0.86-1.26) and absent (all-cause death, HR: 0.91, 95% CI: 0.73-1.14; CV death, HR: 0.77, 95% CI: 0.57-1.02) in patients in the third ADPN tertile (Figure 3 ). The effect modification by ADPN on the resistin-CV mortality link remained significant (P = 0.006) also after shrinkage correction accounting for over-fitting. No interaction was found between ADPN and resistin with CRP, IL-6 and TNF-α (all P = NS). Forcing plasma leptin, insulin and HOMA-IR into the multivariate models of all-cause and CV death did not affect the strength of the relationship between the resistin-ADPN interaction term and all-cause (P = 0.01) and CV mortality (P < 0.001).
D I S C U S S I O N
Resistin is markedly raised in ESKD patients, is weakly related with inflammation, does not associate with insulin sensitivity and correlates inversely with ADPN. Furthermore, the association of resistin with all-cause death and fatal CV events is strongly dependent (effect modification) on concurrent ADPN levels, being apparent and highly significant only in patients with low ADPN. This finding implies that high ADPN acts as a factor protecting from the noxious health effects of increased resistin in this population.
Adipocytes are considered as the sole source of resistin in mice [6, 7] where this adipokine is implicated in insulin resistance and hyperglicaemia [6, 7, 10] . In man, this molecule is expressed primarily in macrophages and is involved in inflammatory processes [8, 13] . It is interesting to note that F I G U R E 1 : Distribution of plasma resistin in the study population. All ESKD patients exceeded the upper limit (29.9 ng/mL) of the normal range (the grey area to the left of the graph).
F I G U R E 2 : Correlation between plasma resistin and adipokines. plasma resistin correlates more closely with inflammation than with insulin resistance in overweight subjects as well as in patients with chronic kidney disease [23] [24] [25] . Plasma resistin is markedly elevated in ESKD [26, 27] , and it is still debated whether this phenomenon is a mere consequence of accumulation secondary to reduced renal clearance and if it may also reflect chronic inflammation [27] . We found that resistin in ESKD patients was not only higher than in normal subjects, but also significantly related with the serum level of CRP while it did not correlate with insulin resistance as assessed by circulating levels of insulin and HOMA-IR index, a finding confirming observations in pre-dialysis CKD patients [26] . Resistin exerts a pro-inflammatory effect on vascular endothelial cells via upregulation of endothelin-1, vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 [28, 29] , which are all critical mediators of the early steps of the atherosclerosis process [30] . In diabetic and non-diabetic patients, plasma resistin levels associate with inflammatory markers as well as with coronary artery calcification [14] . Of note, recent evidence points to resistin as a cogent predictor of incident CHD and CHF in the general population [31] . High resistin is also strongly and independently associated with major CV events and all-cause mortality in type 2 diabetes patients [32] . However, in patients with stable CHD, the association between resistin and mortality in an unadjusted analysis was largely due to confounding by traditional CV risk factors and CKD [15] .
Risk for all-cause and CV death associated with resistin in ESKD The association between resistin and major clinical outcomes such as mortality and CV events was tested in two studies in patients with CHD [15] or fatal myocardial infarction [16] and in both studies high resistin signalled a high death risk or an increased incidence of heart failure. ESKD patients are a population with exceedingly high risk for death and CV events [33] . Causal risk factors for such a high risk are Data are expressed as hazard ratio, 95% CI and P-value. *P = 0.006 after Shrinkage correction for over-fitting (see Methods-Statistical Analysis for more details).
still not well defined and therefore it is relevant to test the hypothesis that resistin is implicated in this high risk with aetiologic and prognostic implications. In this regard, our study is the very first investigating the relationship between resistin and major clinical outcomes in ESKD. We found that resistin predicted death and fatal CV outcomes in individuals with low ADPN but not in those with normal or high ADPN. This association was statistically strong and quantitatively of potential clinical relevance. The effect modification by ADPN on the relationship between resistin and mortality and fatal CV events has biological plausibility because ADPN and resistin have opposite effects on endothelial function and on the atherosclerotic process, resistin being a noxious factor for the CV system and ADPN a protective one. Of note, in our study the effect modification by ADPN on the resistin-mortality and resistin-CV mortality relationships was fully independent of potential confounders, including traditional CV risk factors as well as risk factors peculiar to ESKD, including haemoglobin, albumin and CRP.
In conclusion, we found that in ESKD, ADPN is a modifier of the link between resistin and mortality. Indeed, the risk for all-cause and CV mortality portended by a fixed increase in plasma resistin is evident in patients with low levels of ADPN but absent in those with high levels of this adipokine. These data underscore the importance of interaction analysis among adipokines to fully capture the relevance of their associations with adverse clinical events in the ESKD population.
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